Sign in
Not yet recruitingNo phase

Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis

Key facts

Who runs it
yilong Wang
Where
China6 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
86 people, planned
Started
1 Apr 2026
Expected to end
1 Jul 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Intracalvariosseous injection vancomycin/tigecycline/polymyxin B
  • Intravenous injection vancomycin/tigecycline/polymyxin B
  • Conventional treatment
Record updated
27 March 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • 1. Age 18-75 years, gender not limited
  • 2. Meeting the diagnostic criteria for moderate to severe bacterial meningitis:; Meeting the diagnostic criteria for bacterial meningitis, i.e., meeting at least item i:; Abnormal body temperature (>38℃ or <36℃), turbid or purulent Cerebrospinal fluid (CSF) , CSF leukocytosis (>500×10⁶/L), CSF glucose/serum glucose concentration <0.4, CSF protein concentration >50mg/dL, meeting the clinical diagnosis; ii. In addition to item i, positive microbial tests or cultures of specimen smears, drainage tube heads, implants, and CSF (excluding contamination and colonization), meeting the etiological diagnosis; GCS score ≤12 points or a decrease of 2 points from the previous score; At least one of the following conditions is present: altered consciousness, seizures, brain parenchymal involvement, severe manifestations such as mechanical ventilation or circulatory support
  • 3. After 48-72 hours of antibiotic treatment, if the investigator determines that the patient's condition shows no significant improvement or continues to worsen, or if at least one of the following conditions is present:; Symptoms and signs related to intracranial infection show no trend of relief or worsen; CSF white blood cell count shows no trend of decrease, or increases after decreasing; CSF protein concentration shows no trend of decrease, or increases after decreasing; CSF/serum glucose concentration shows no trend of increase, or decreases after increasing; CSF bacterial culture remains positive or becomes positive again after initially being negative
  • 4. Based on the patient's condition, treatment with polymyxin B, tigecycline, or vancomycin may be necessary
  • 5. Obtain informed consent

Who cannot take part

  • 2. Received intrathecal or intraventricular antibiotic treatment before randomization
  • 15. Patients currently participating in other interventional trials or who have used other investigational drugs within one month or five drug half-lives
  • 1. History of allergy to polymyxin B, tigecycline, or vancomycin
  • 3. Patients with severe pulmonary infection/acute respiratory distress syndrome (PaO₂/FiO₂ < 150 mmHg, FiO₂ ≥ 0.6, PEEP ≥ 5 cmH₂O) or whose primary cause of mechanical ventilation is not determined to be intracranial infection
  • 9. Within the past 3 months, the patient has experienced an acute ST-segment elevation myocardial infarction and/or decompensated heart failure (meeting New York Heart Association [NYHA] functional class III or IV)
  • 12. Patients with positive hepatitis C virus antibody or a history of positive testing
  • 13. Patients with positive HIV test or a history of positive testing
  • 4. Patients with a primary extracranial infection focus (e.g., lungs, abdomen, urinary tract, etc.) who, after adequate fluid resuscitation, require vasoactive drugs to maintain MAP ≥ 65 mmHg (e.g., norepinephrine ≥ 0.25 μg/kg/min) and lactate > 2 mmol/L, or whose primary cause of critical illness is not determined to be intracranial infection
  • 7. Bleeding tendency deemed unfavorable for the procedure by the investigator: abnormal coagulation function (e.g., platelet count <50×10⁹/L; prothrombin time [PT]>3s), patients with a previous diagnosis of hemophilia or other coagulation disorders
  • 8. Patients with severe hepatic or renal insufficiency (where severe hepatic insufficiency is defined as alanine aminotransferase (ALT) value ≥3 times the upper limit of normal (ULN) or aspartate aminotransferase (AST) value ≥3 times the ULN; severe renal insufficiency is defined as serum creatinine (CRE) ≥1.5 times the ULN or glomerular filtration rate (eGFR) <40 mL/min/1.73m²
  • 10. Patients with severe or extremely severe anemia (hemoglobin < 60 g/L) at the time of randomization
  • 11. Patients with active hepatitis B infection (positive hepatitis B surface antigen and/or positive serum HBV DNA or serum HBV DNA > 2 × 10⁸ IU/ml)
  • 5. Patients with contraindications to transcranial administration, such as severe skull fracture, poor visualization of the skull diploic, or planned decompressive craniectomy, which may affect transcranial administration
  • 6. Clinical signs of brain herniation, such as unilateral or bilateral pupillary dilation and fixation; or loss of other brainstem reflexes determined by the investigator to be caused by meningitis or brain herniation; or other uncontrollable signs of unstable vital signs
  • 14. Pregnant, lactating, or potentially pregnant patients, or patients planning to become pregnant
  • 16. Patients deemed unsuitable for participation in this study by the investigator

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Multiple preclinical and clinical studies, including the investigators' published work and the ongoing SOLUTION series, have consistently demonstrated that intracalvariosseous (ICO) injection can markedly increase drug exposure within the central nervous system with acceptable safety. This trial is designed to further evaluate the efficacy and safety of antibiotic delivery via the ICO route in the treatment of bacterial meningitis, particularly in patients with moderate-to-severe disease who have shown an inadequate response to standard therapy.

The 2 groups in the trial

  • Intracalvariosseous injection + Intravenous injectionTreatment being tested

    In patients who fail to respond to the initial intravenous antibiotic regimen, intravenous treatment will be switched to the indicated antibiotic (polymyxin B, tigecycline, or vancomycin). At the same time, bilateral parietal outer-table drill holes will be created, delivery devices will be secured, and the corresponding antibiotic will be continuously infused via the intracalvariosseous route. The combined ICO and intravenous treatment will be administered concurrently for 7 × 24 hours, after which the ICO devices will be removed. The duration of intravenous therapy will then be adjusted according to treatment response, including clinical symptoms, signs, and laboratory findings. If a change in antibiotic selection is required during the period of combined treatment, the antibiotic administered via the intracalvariosseous route must remain consistent with that administered intravenously.

    Treatment: Intracalvariosseous injection vancomycin/tigecycline/polymyxin B, Intravenous injection vancomycin/tigecycline/polymyxin B, and Conventional treatment

  • Intravenous injectionExisting treatment, for comparison

    In patients who fail to respond to the initial intravenous antibiotic regimen, intravenous treatment will be switched to the indicated antibiotic (polymyxin B, tigecycline, or vancomycin). The duration of intravenous therapy will be adjusted according to treatment response, including clinical symptoms, signs, and laboratory findings.

    Treatment: Intravenous injection vancomycin/tigecycline/polymyxin B and Conventional treatment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Intracalvariosseous Combined With Intravenous Injection of Antibiotics in Moderate-to-Severe Bacterial Meningitis
Fit questions
Built from NCT07495150, who can take part
Record updated
27 March 2026